Favorable Trial Results Confirmed Regeneron Gout Drug

Regeneron Pharmaceuticals Inc. said Monday its drug Arcalyst was effective in reducing gout flares based on its second Phase III study.

Regeneron Pharmaceuticals has reported that allopurinol therapy Arcalyst (rilonacept) has met all of the primary and secondary study endpoints of its second Phase III study, which evaluated the drug in gout patients.

The primary endpoint of the study was the number of gout flares per patient over the 16-week treatment period.

Patients who were treated with Arcalyst at a weekly, self-administered, subcutaneous dose of either 160mg or 80mg experienced a 72% decrease in the mean number of gout flares compared to the placebo group.

Arcalyst also met all the secondary endpoints of the study. Compared to the placebo, Arcalyst reduced the proportion of patients who e